A growing body of research suggests the involvement of immune system factors in central nervous system development and in pathophysiology related to schizophrenia.
Molecular research has demonstrated that numerous CNS cell types produce a wide variety of both pro-and anti-inflammatory cytokines. 3 These cytokines mediate responses to pathological insults and also influence normal physiological activities as diverse as neuronal development, neurite outgrowth, and nerve cell degeneration. 4 They also modulate the activity and level of expression of neurotransmitters such as dopamine, serotonin, noradrenaline, and neuropeptide Y. 5 Related to these findings from basic research, clinical investigations have demonstrated abnormal plasma levels of cytokines such as tumor necrosis factor-␣ (TNF␣), 6 IL-2, 7 and IL-6 6 in subjects with schizophrenia. Naudin et al, 8 for example, recently reported that elevated plasma levels of IL-6 were correlated with duration of illness while elevated TNF␣ levels were not. Based on this, they hypothesized that the IL-6 abnormality represented a clinical state marker whereas the TNF␣ abnormality reflected one element in a more stable genetic trait background that conferred schizophrenia susceptibility.
A logical next step, therefore, is to directly investigate the contribution of immune system molecules to the genetic predisposition to develop schizophrenia. We have pursued this, beginning with the TNF␣ receptor TNF-RII. TNF-RII is one of two soluble TNF␣ receptors (the other being TNF-RI) that are widely expressed in fetal brain tissue. 9 When expressed at low levels, these receptors appear to maintain a reservoir of TNF␣ that is available for graded release; high levels, conversely, may inhibit the activity of TNF␣.
1 While plasma levels of TNF-RII have been found to be normal in subjects with schizophrenia, 8 protein level may be unrelated to genetic variability, and TNF-RII is a reasonable candidate gene for the disease.
A second aspect of this study is an examination of the relationship between variability in TNF-RII and brain morphology. Abnormal brain morphology is one of the most consistent pathophysiological findings in subjects with schizophrenia. While the most widely replicated abnormality is enlargement of the cerebral ventricles, 10 differences between subjects and controls have been reported for virtually all brain regions studied. 11 Importantly, many of these abnormalities have been found in subjects who are in the early stages of illness, 12, 13 supporting the hypothesis that such abnormalities, as well as schizophrenia itself, may arise from disrupted early brain development. Altered expression of cytokines and their receptors in mice have produced a variety of brain abnormalities; 14 the absence specifically of TNF␣ receptors has been associated with decreased neuronal survival and increased damage in response to noxious stimuli. 15 Given this body of evidence, it is plausible that variability in TNF-RII might be associated with variability in adult brain morphology.
We searched, therefore, for associations between TNF-RII and schizophrenia, and between TNF-RII and brain morphology in subjects with schizophrenia, using a bi-allelic marker in the 3Ј UTR of TNF-RII. Table 1 shows the counts of alleles 1 and 2 in the entire sample of probands and controls; the frequency differences were not significant. Likewise, there was no difference in the transmission of either allele in 62 proband-parent trios, as shown in Table 2 . Table 3 displays demographic data for 86 subjects who were included in the imaging portion of the study. Fifty-one subjects had at least one copy of allele 2, 27.5 ± 6.5 a (t = −2.74, df = 1, P = 0.008; F = 1.99, P = 0.03). whereas the other 37 were homozygous for allele 1. There were no differences in gender composition between the two groups. The age at the time of imaging of subjects homozygous for allele 1, however, was younger and had less variance than that of subjects with at least one copy of allele 2. Table 4 displays the results of the covariance analyses comparing regional brain morphology between subMolecular Psychiatry jects with and without allele 2. Using a P value of 0.05, the tests showed that ventricular volume was significantly different between the two groups (F = 4.87, df = 1, P = 0.03) while frontal lobe volume differences approached significance (F = 3.65, df = 1, P = 0.06). Partial correlations of these regional volumes demonstrated that the ventricles were larger and the frontal lobes smaller in subjects homozygous for allele 1. It should be noted, however, that these tests would not meet more conservative significance criteria using P values adjusted for multiple tests (P = 0.05/6 tests = 0.083).
No relationship was found, therefore, between the gene coding for TNF-RII and schizophrenia in either the population-based association test or the familybased TDT. When examining the relationship of this polymorphism with brain morphology, however, we found interesting results. Subjects homozygous for allele 1 had larger ventricles and smaller frontal lobes than did those with at least one copy of allele 2. Thus, while TNF-RII itself is unlikely to contribute significantly to the genetic predisposition to develop schizophrenia, it may alter or modulate the phenotypic expression of the disorder.
To explore this idea further, and given the difference in age at the time of imaging based on genotype, we investigated whether age at onset of illness also differed between the two groups. Age of onset of illness was defined as the age when the subject first experienced psychiatric symptoms. Estimates had been gathered using the CASH and were available for 79 of the subjects who were imaged. A t-test showed that homozygotes for allele 1 had an earlier age of onset with a trend towards less variance than subjects with at least one copy of allele 2 (Table 5 ). This suggests a phenotype of larger ventricles, smaller frontal lobes, and earlier, less variable age at onset in subjects with schizophrenia homozygous for allele 1 of TNF-RII.
The ability of TNF-RII to potentially influence brain morphology in this way is supported by a variety of data. TNF␣ is secreted by microglia and astrocytes which are present early in the developing brain.
3 TNF␣ can induce nerve growth factor release from astrocytes and interacts with the neural cellular adhesion molecule (N-CAM), a molecule that participates in a variety of developmental processes. 16 Mouse knockouts deficient in TNF␣ receptors, when compared to wildtype mice, exhibit a general decrease in neuronal survival and increased neuronal degeneration in response to a variety of specific stressors. 15, 17 This finding has 21 Furthermore, TNF␣ injections in mice have been found to activate the hypothalamic-pituitary-adrenal axis and to alter CNS concentrations of neurotransmitters such as serotonin, noradrenaline, and dopamine. [22] [23] [24] Any or all of these activities could affect brain development and ultimate adult brain morphology.
There are only a small number of previous studies that have directly examined relationships between genetic variability and brain morphology. Some family studies have incorporated obtaining MRIs and measuring brain morphology in first-degree relatives of individuals with schizophrenia. 25, 26 These studies have reported that certain abnormalities tend to run in families, implying that they are heritable, while others do not, though the specific heritable dysmorphologies are not consistent across studies. Furthermore, without molecular information, these studies cannot link the brain abnormalities to specific genetic factors. Studies attempting to bridge this gap are scant. Shihabuddin et al 27 reported associations of ventricular volume, ventricle-to-brain ratio, and parietal CSF volume to a chromosome 5 marker previously linked to schizophreniarelated disorders in a single extended pedigree. We have previously examined brain derived neurotrophic factor (BDNF) as a candidate gene for schizophrenia. While we found no evidence for its heritability, we did find that variability in a BDNF polymorphism was associated with variability in regional brain tissue volume, specifically in the parietal lobe. 28 Further interpretation of the data presented in this study, however, is hindered by a number of limitations. First is our modest sample size, which inhibits our ability to definitively rule out an association. The power of a study to detect an association is difficult to determine, as it is dependent, among other factors, on the true mode of heritability which, for schizophrenia, is unknown. Given, however, that the effects of most schizophrenia susceptibility genes are likely to be small, we may simply be unable to detect a true association in our current sample. Second, we lack a comparison group for the brain morphology findings. We are therefore unable to determine whether the observed relationships are unique to schizophrenia or represent more generalized phenomena that operate independently of illness. Lastly, the current state of knowledge regarding the function of TNF-RII and the specific polymorphism that we examined (ie, whether it affects gene function or expression) is limited, hindering our ability to understand how its variability could produce the effect we observed.
Nonetheless, the data presented here further the effort to link phenotype with genotype in the context of a genetically complex disorder. While we found no support for the TNF-RII as a disease gene for schizophrenia, our data suggest that this gene may influence adult brain morphology and age of onset in subjects with the disorder. Further studies are required to support this finding and, if validated, to determine whether it is confined to schizophrenia or represents a more generalized phenomenon. Investigations such as this may ultimately aid in the effort to identify homogeneous subgroups or endophenotypes within the broad spectrum of schizophrenic illnesses.
Materials and methods

Subjects
All subjects were recruited through the University of Iowa Mental Health Clinical Research Center (MHCRC), after being diagnosed with either schizophrenia or schizophreniform disorder according to DSM-III-R or DSM-IV criteria using the CASH semistructured interview instrument. 29 This provided 140 probands, 134 with schizophrenia and six with schizophreniform disorder. Thirty-five (25%) of the subjects were female and 105 (75%) were male. Comparison DNA was gathered from parents of probands and from individuals participating as normal control subjects in other CRC protocols. Altogether, 81 fathers, 116 mothers, and 46 CRC control subjects provided DNA, for a total of 243 comparison subjects. The parental DNA provided 62 proband-parent trios with which to test for linkage disequilibrium. All participating individuals provided written informed consent.
Genetic analyses DNA was extracted from whole blood using standard procedures. PCR was then performed for a singlestrand conformational polymorphism located in the 3Ј untranslated region of TNFR-II, 30 with products resolved on 5% non-denaturing sequencing gels and visualized using standard silver staining techniques.
The possibility of association was tested by comparing allele frequencies from all probands with frequencies from all controls using a chi-square test for differences. The possibility of linkage disequilibrium was tested in the 62 parent proband trios using the TDT statistic. 31 
Imaging analyses
Image analysis was performed on a subgroup of 86 probands who had participated in CRC imaging protocols during which they received a high quality magnetic resonance imaging (MRI) brain scan. Eighty-four of these subjects had schizophrenia, two had schizophreniform disorder; 65 (75.6%) were male and 21 (24.4%) female; their average age at the time of imaging was 30.2 ± 8.4 years. Three different imaging sequences (T1, T2, and proton density) were acquired according to previously defined parameters 10 using a 1.5 Tesla GE Signa magnetic resonance scanner.
After acquisition, the data were processed using locally developed software (BRAINS 32, 33 ). An artificial neural net was used to 'cut' the brain out of the skull. 34 The data were then realigned transaxially with the AC-PC line and coronally with the interhemispheric fissure, followed by the three MR images being co-regis-tered and resampled three-dimensionally. 35 Brain tissue was then classified into gray matter, white matter, and cerebro-spinal fluid (CSF) using a multi-spectral discriminant analysis-based segmentation algorithm. 36 To obtain measurements of regional tissue volume, the three-dimensional brain images were subjected to a linear transformation into Talairach atlas space. 37 Gray matter, white matter, and CSF volumes within these regions were then calculated. 38 For this study, six regions of interest were examined: total gray and white matter volumes for the bilateral frontal, temporal, parietal, and occipital lobes; total gray and white matter volume for the cerebellum; and total CSF volume for the cerebral ventricles.
To examine allelic effects on brain morphology, subjects were divided into two genetically defined groups: those with at least one copy of allele 2 and those homozygous for allele 1 (the high prevalence of allele 1 led to the vast majority of subjects having at least one copy, limiting its ability to define meaningful subgroups). Analysis of covariance was then used to compare tissue volumes between these two groups. Region of interest volumes were the dependent variables, allelic group was the independent variable, and age at the time of imaging and total cranial volume were included as covariates.
